PBLCX
Price
$44.71
Change
+$0.58 (+1.31%)
Updated
Sep 4 closing price
Net Assets
11.63B
RGEBX
Price
$82.44
Change
+$0.19 (+0.23%)
Updated
Sep 5 closing price
Net Assets
331.65B
Interact to see
Advertisement

PBLCX vs RGEBX

Header iconPBLCX vs RGEBX Comparison
Open Charts PBLCX vs RGEBXBanner chart's image
Principal Blue Chip C
Price$44.71
Change+$0.58 (+1.31%)
VolumeN/A
Net Assets11.63B
American Funds Growth Fund of Amer R2E
Price$82.44
Change+$0.19 (+0.23%)
VolumeN/A
Net Assets331.65B
PBLCX vs RGEBX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
PBLCX vs. RGEBX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBLCX is a Hold and RGEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGEBX has more cash in the bank: 332B vs. PBLCX (11.6B). PBLCX (0.00) and RGEBX (0.00) have matching dividends . PBLCX was incepted earlier than RGEBX: PBLCX (12 years) vs RGEBX (11 years). PBLCX (1.69) is less costly to investors than RGEBX (1.09). RGEBX is a more actively managed with annual turnover of: 25.00 vs. PBLCX (14.70). RGEBX has a lower initial minimum investment than PBLCX: RGEBX (250) vs PBLCX (1000). RGEBX annual gain was more profitable for investors over the last year : 17.32 vs. PBLCX (13.48). PBLCX return over 5 years is better than : 44.09 vs. RGEBX (38.39).
PBLCXRGEBXPBLCX / RGEBX
Total Expense Ratio1.661.09152%
Annual Report Gross Expense Ratio1.691.09155%
Fund Existence12 years11 years-
Gain YTD11.41315.13275%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets11.6B332B3%
Annual Yield % from dividends0.000.00-
Returns for 1 year13.4817.3278%
Returns for 3 years65.7857.24115%
Returns for 5 years44.0938.39115%
Returns for 10 years191.8491.00211%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARTV3.610.50
+16.08%
Artiva Biotherapeutics Inc
ARCT17.851.09
+6.50%
Arcturus Therapeutics Holdings
MANH215.315.45
+2.60%
Manhattan Associates
TRMD23.020.25
+1.10%
TORM plc
INDP3.30-1.31
-28.35%
Indaptus Therapeutics Inc